Ledraxen (Enoxaparin Sodium)

Enoxaparin Sodium enhances the activity of antithrombin III, which in turn inhibits factor Xa and, to a lesser extent, factor IIa (thrombin). By blocking these key steps in the coagulation cascade, the drug reduces fibrin formation and limits clot development.

The specific dose of Ledraxen is individualized by the prescribing clinician based on the patient’s indication, weight, renal function, and other clinical factors. Dosage regimens are not standardized in public literature and must be determined by a qualified healthcare professional.

The safety of Ledraxen in pregnancy or while breastfeeding has not been definitively established. It should only be used if the potential therapeutic benefit justifies any possible risk to the fetus or infant, and this decision must be made by the treating physician.

To order Ledraxen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Ledraxen (enoxaparin) is a low molecular weight heparin offering more predictable pharmacokinetics, a longer half‑life and once‑ or twice‑daily dosing, whereas unfractionated heparin requires continuous infusion and frequent monitoring of activated partial thromboplastin time. Both provide anticoagulation, but enoxaparin generally has a lower risk of heparin‑induced thrombocytopenia.

Ledraxen should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze the product or shake it vigorously. Keep the vial in its original packaging until use to maintain sterility and potency.

Ledraxen is administered by subcutaneous injection or, when required, by intravenous infusion. The injection site is typically the abdomen or thigh, and the technique should follow aseptic guidelines. Dosing intervals are determined by the prescriber based on the clinical indication.

The most serious risks include major bleeding events such as intracranial hemorrhage, heparin‑induced thrombocytopenia (HIT), and spinal or epidural hematoma, especially when combined with neuraxial procedures. Prompt recognition of unusual bleeding or a rapid drop in platelet count is essential.

Ledraxen is contraindicated in patients with active major bleeding, known hypersensitivity to enoxaparin or other LMWHs, and those with a history of HIT. Caution is also advised for individuals with severe renal impairment, uncontrolled hypertension, or recent intracranial surgery.